Chemokine receptors

X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Chemokine receptors, Branches of biology, CXCR4, Canaccord Genuity, CXC chemokine receptors, Genuity, HIV, Chemokine

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuitys 41st Annual Growth Conference on Thursday, August 12, 2021.

Key Points: 
  • BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuitys 41st Annual Growth Conference on Thursday, August 12, 2021.
  • A live webcast of the fireside chat from the Canaccord Genuity 41st Annual Growth Conference will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcast, the event will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • The companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.

Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist

Retrieved on: 
Tuesday, June 8, 2021
Clinical medicine, Medicine, Chemokine receptors, Antineoplastic drugs, Branches of biology, HIV/AIDS, Cancer treatments, CXCR4, Eribulin, Tat

Klimkait, Shorr, and Ghosn will be available to answer questions following the formal presentations.

Key Points: 
  • Klimkait, Shorr, and Ghosn will be available to answer questions following the formal presentations.
  • Polyphor's management team will then discuss novel research findings of balixafortide relevant for COVID-19 infections.
  • Balixafortide is a potent, selective CXCR4 antagonist which is currently also in Phase III development in combination with eribulin in patients with metastatic HER-2 negative breast cancer.
  • is Head, Pulmonary and Critical Care Medicine at Medstar Washington Hospital Center and a Professor of Medicine at Georgetown University.

X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Chemokine receptors, CXCR4, CXC chemokine receptors, Chemokine

The data will be presented in an e-Poster at this years European Hematology Association (EHA) Annual Congress, taking place virtually from June 9-17, 2021.

Key Points: 
  • The data will be presented in an e-Poster at this years European Hematology Association (EHA) Annual Congress, taking place virtually from June 9-17, 2021.
  • The X4 Pharmaceuticals conference call can be accessed by dialing (866) 721-7655 (domestic) or (409) 216-0009 (international), followed by the conference ID: 4492859.
  • The live webcast will be accessible on the Events & Presentation page of the companys website at investors.x4pharma.com .
  • The companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.

X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences

Retrieved on: 
Monday, May 17, 2021
Chemokine receptors, Branches of biology, CXCR4, CXC chemokine receptors, Chemokine

The company\xe2\x80\x99s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.

Key Points: 
  • The company\xe2\x80\x99s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.
  • X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates.
  • For more information, please visit www.x4pharma.com .\n'

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Drugs, Chemokine receptors, Biology, CXCR4, Magnesium in biology, Medroxyprogesterone acetate, CXC chemokine receptors

Mavorixafor escalation to 400 mg occurs after 28 days if no dose-limiting toxicities are observed, and to 600 mg after 400 mg is deemed safe.

Key Points: 
  • Mavorixafor escalation to 400 mg occurs after 28 days if no dose-limiting toxicities are observed, and to 600 mg after 400 mg is deemed safe.
  • The company\xe2\x80\x99s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • Forward-looking statements include, without limitation, statements regarding statements regarding the clinical development of mavorixafor and X4\xe2\x80\x99s other product candidates or programs.
  • X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.\n"

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Cytokines, Chemokine receptors, Clusters of differentiation, C-C chemokine receptor type 7, CCL21, Angiology, Dendritic cell, Neuropilin 2, Forward-looking statement, Lymphatic system

\xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.

Key Points: 
  • \xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.
  • In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs.
  • All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain.
  • Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n'

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

Retrieved on: 
Thursday, April 22, 2021
Branches of biology, Chemokine receptors, Signal transduction, CXCR4, CXC chemokine receptors, XC2, Chemokine, Receptor antagonist

The conference call can be accessed by dialing (866) 721-7655 from\xc2\xa0the United States\xc2\xa0or (409) 216-0009 internationally, followed by the conference ID: 5658628.

Key Points: 
  • The conference call can be accessed by dialing (866) 721-7655 from\xc2\xa0the United States\xc2\xa0or (409) 216-0009 internationally, followed by the conference ID: 5658628.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals\xe2\x80\x99 website at www.x4pharma.com .
  • The company\xe2\x80\x99s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting

Retrieved on: 
Saturday, April 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Proteins, Branches of biology, Selectins, Integral membrane proteins, Chemokine receptors, Clusters of differentiation, CXCR4, E-selectin, American Association for Cancer Research, GMI-1359, GlycoMimetics, Inc.

The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21.

Key Points: 
  • The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21.
  • The clinical poster concludes that GMI-1359 demonstrated an acceptable safety and tolerability profile in the patients treated to date.
  • These findings on immune cell redistributions strongly suggest the induction of a more favorable anti-tumor environment following GMI-1359 administration.
  • GlycoMimetics has an ongoing Phase 1b clinical trial evaluating its wholly-owned drug candidate GMI-1359, a combined CXCR4 and E-selectin antagonist.

X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Chemokine receptors, Branches of biology, CXCR4, CXC chemokine receptors, HIV, Chemokine

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.

Key Points: 
  • BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.
  • A live webcast of the presentation from the Needham Virtual Healthcare Conference will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcast, the event will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • The companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.

RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Cytokines, Cell biology, Immune system, Clusters of differentiation, Chemokine receptors, CCL17, CCL22, CCR4, Regulatory T cell, Mesothelioma, C-Met

Treg express CCR4 and migrate toward CCL17 and CCL22 which are frequently upregulated in a subset of tumors or increased following immunotherapy.

Key Points: 
  • Treg express CCR4 and migrate toward CCL17 and CCL22 which are frequently upregulated in a subset of tumors or increased following immunotherapy.
  • In a murine mesothelioma model, a combination of CAR- T-cells plus CCR4 antagonist significantly slowed tumor growth and significantly improved survival compared to untreated control.
  • RAPTs small-molecule compounds demonstrated potent inhibition of HPK1 in biochemical assays, reduction of levels of phosphorylated SLP76 and concomitant increase in IL-2 production.
  • Recent advances in cancer metabolism suggest that targeting amino acid metabolism represents a promising strategy for the development of novel therapeutic agents.